Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.

Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P, Thomas R, Kille J, Baril JG, Cox J, Giguere P, Harris M, Hughes C, MacPherson P, O'Donnell S, Reimer J, Singh A, Barrett L, Bogoch I, Jollimore J, Lambert G, Lebouche B, Metz G, Rogers T, Shafran S; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.

CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494. No abstract available. Erratum in: CMAJ. 2018 Jun 25;190(25):E782.

2.

Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.

Drost SA, Wentzell JR, Giguère P, McLurg DL, Sabloff M, Kanji S, Nguyen TT.

Pharmacotherapy. 2017 Jun;37(6):684-691. doi: 10.1002/phar.1935. Epub 2017 May 12.

PMID:
28394433
3.

Propagation of the Allosteric Modulation Induced by Sodium in the δ-Opioid Receptor.

Sun X, Laroche G, Wang X, Ågren H, Bowman GR, Giguère PM, Tu Y.

Chemistry. 2017 Apr 3;23(19):4615-4624. doi: 10.1002/chem.201605575. Epub 2017 Mar 20.

PMID:
28182309
4.

Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists.

Cheng J, McCorvy JD, Giguere PM, Zhu H, Kenakin T, Roth BL, Kozikowski AP.

J Med Chem. 2016 Nov 10;59(21):9866-9880. Epub 2016 Oct 25.

PMID:
27726356
5.

Structure-based discovery of opioid analgesics with reduced side effects.

Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang XP, Sassano MF, Giguère PM, Löber S, Da Duan, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK.

Nature. 2016 Sep 8;537(7619):185-190. doi: 10.1038/nature19112. Epub 2016 Aug 17.

6.

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.

Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C.

Can J Infect Dis Med Microbiol. 2016;2016:4385643. doi: 10.1155/2016/4385643. Epub 2016 Jul 4.

7.

Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients.

Chowdhry U, Jacques A, Karovitch A, Giguère P, Nguyen ML.

Can J Hosp Pharm. 2016 May-Jun;69(3):194-201. Epub 2016 Jun 30.

8.

Addition of 25-hydroxyvitamin D levels to the Deyo-Charlson Comorbidity Index improves 90-day mortality prediction in critically ill patients.

Mahato B, Otero TM, Holland CA, Giguere PT, Bajwa EK, Camargo CA Jr, Quraishi SA.

J Intensive Care. 2016 Jun 17;4:40. doi: 10.1186/s40560-016-0165-0. eCollection 2016.

9.

Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.

Mistry M, Shea A, Giguère P, Nguyen ML.

Ann Pharmacother. 2016 Jun;50(6):455-62. doi: 10.1177/1060028016641427. Epub 2016 Apr 5.

PMID:
27048188
10.

In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.

Farrell MS, McCorvy JD, Huang XP, Urban DJ, White KL, Giguere PM, Doak AK, Bernstein AI, Stout KA, Park SM, Rodriguiz RM, Gray BW, Hyatt WS, Norwood AP, Webster KA, Gannon BM, Miller GW, Porter JH, Shoichet BK, Fantegrossi WE, Wetsel WC, Roth BL.

PLoS One. 2016 Mar 10;11(3):e0150602. doi: 10.1371/journal.pone.0150602. eCollection 2016.

11.

Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.

Sulpher J, Giguere P, Hopkins S, Dent S.

Support Care Cancer. 2016 Jul;24(7):3185-9. doi: 10.1007/s00520-016-3143-0. Epub 2016 Mar 3.

PMID:
26939922
12.

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.

Cheng J, Giguere PM, Schmerberg CM, Pogorelov VM, Rodriguiz RM, Huang XP, Zhu H, McCorvy JD, Wetsel WC, Roth BL, Kozikowski AP.

J Med Chem. 2016 Jan 28;59(2):578-91. doi: 10.1021/acs.jmedchem.5b01153. Epub 2016 Jan 13.

PMID:
26704965
13.
14.

A Non-Canonical Function of Gβ as a Subunit of E3 Ligase in Targeting GRK2 Ubiquitylation.

Zha Z, Han X, Smith MD, Liu Y, Giguère PM, Kopanja D, Raychaudhuri P, Siderovski DP, Guan KL, Lei QY, Xiong Y.

Mol Cell. 2015 Jun 4;58(5):794-803. doi: 10.1016/j.molcel.2015.04.017. Epub 2015 May 14.

15.

A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior.

Vardy E, Robinson JE, Li C, Olsen RHJ, DiBerto JF, Giguere PM, Sassano FM, Huang XP, Zhu H, Urban DJ, White KL, Rittiner JE, Crowley NA, Pleil KE, Mazzone CM, Mosier PD, Song J, Kash TL, Malanga CJ, Krashes MJ, Roth BL.

Neuron. 2015 May 20;86(4):936-946. doi: 10.1016/j.neuron.2015.03.065. Epub 2015 Apr 30.

16.

PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome.

Kroeze WK, Sassano MF, Huang XP, Lansu K, McCorvy JD, Giguère PM, Sciaky N, Roth BL.

Nat Struct Mol Biol. 2015 May;22(5):362-9. doi: 10.1038/nsmb.3014. Epub 2015 Apr 20.

17.

Structural basis for bifunctional peptide recognition at human δ-opioid receptor.

Fenalti G, Zatsepin NA, Betti C, Giguere P, Han GW, Ishchenko A, Liu W, Guillemyn K, Zhang H, James D, Wang D, Weierstall U, Spence JC, Boutet S, Messerschmidt M, Williams GJ, Gati C, Yefanov OM, White TA, Oberthuer D, Metz M, Yoon CH, Barty A, Chapman HN, Basu S, Coe J, Conrad CE, Fromme R, Fromme P, Tourwé D, Schiller PW, Roth BL, Ballet S, Katritch V, Stevens RC, Cherezov V.

Nat Struct Mol Biol. 2015 Mar;22(3):265-8. doi: 10.1038/nsmb.2965. Epub 2015 Feb 16.

18.

Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.

Cheng J, Giguère PM, Onajole OK, Lv W, Gaisin A, Gunosewoyo H, Schmerberg CM, Pogorelov VM, Rodriguiz RM, Vistoli G, Wetsel WC, Roth BL, Kozikowski AP.

J Med Chem. 2015 Feb 26;58(4):1992-2002. doi: 10.1021/jm5019274. Epub 2015 Feb 10.

19.
20.

G Protein signaling modulator-3 inhibits the inflammasome activity of NLRP3.

Giguère PM, Gall BJ, Ezekwe EA Jr, Laroche G, Buckley BK, Kebaier C, Wilson JE, Ting JP, Siderovski DP, Duncan JA.

J Biol Chem. 2014 Nov 28;289(48):33245-57. doi: 10.1074/jbc.M114.578393. Epub 2014 Sep 30.

21.

Tuning up the right signal: chemical and genetic approaches to study GPCR functions.

Giguere PM, Kroeze WK, Roth BL.

Curr Opin Cell Biol. 2014 Apr;27:51-5. doi: 10.1016/j.ceb.2013.11.006. Epub 2013 Dec 8. Review.

22.
23.

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):217-38. Erratum in: Can J Infect Dis Med Microbiol. 2014;24(1):63.

24.

Molecular control of δ-opioid receptor signalling.

Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, Cherezov V, Roth BL, Stevens RC.

Nature. 2014 Feb 13;506(7487):191-6. doi: 10.1038/nature12944. Epub 2014 Jan 12.

25.

Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition.

Brown DG, Bernstein PR, Griffin A, Wesolowski S, Labrecque D, Tremblay MC, Sylvester M, Mauger R, Edwards PD, Throner SR, Folmer JJ, Cacciola J, Scott C, Lazor LA, Pourashraf M, Santhakumar V, Potts WM, Sydserff S, Giguère P, Lévesque C, Dasser M, Groblewski T.

J Med Chem. 2014 Feb 13;57(3):733-58. doi: 10.1021/jm4014828. Epub 2014 Jan 27.

PMID:
24410637
27.
28.

DREADDs: novel tools for drug discovery and development.

Lee HM, Giguere PM, Roth BL.

Drug Discov Today. 2014 Apr;19(4):469-73. doi: 10.1016/j.drudis.2013.10.018. Epub 2013 Nov 1. Review.

29.

Psychiatric treatment considerations with direct acting antivirals in hepatitis C.

Sockalingam S, Tseng A, Giguere P, Wong D.

BMC Gastroenterol. 2013 May 14;13:86. doi: 10.1186/1471-230X-13-86. Review.

30.

G-protein signaling modulator-3, a gene linked to autoimmune diseases, regulates monocyte function and its deficiency protects from inflammatory arthritis.

Giguère PM, Billard MJ, Laroche G, Buckley BK, Timoshchenko RG, McGinnis MW, Esserman D, Foreman O, Liu P, Siderovski DP, Tarrant TK.

Mol Immunol. 2013 Jun;54(2):193-8. doi: 10.1016/j.molimm.2012.12.001. Epub 2012 Dec 29.

31.

Heterotrimeric G-protein signaling is critical to pathogenic processes in Entamoeba histolytica.

Bosch DE, Kimple AJ, Muller RE, Giguère PM, Machius M, Willard FS, Temple BR, Siderovski DP.

PLoS Pathog. 2012;8(11):e1003040. doi: 10.1371/journal.ppat.1003040. Epub 2012 Nov 15.

32.

Regulation of the subcellular localization of the G-protein subunit regulator GPSM3 through direct association with 14-3-3 protein.

Giguère PM, Laroche G, Oestreich EA, Duncan JA, Siderovski DP.

J Biol Chem. 2012 Sep 7;287(37):31270-9. doi: 10.1074/jbc.M112.394379. Epub 2012 Jul 26.

33.

The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy.

Lei Y, Wen H, Yu Y, Taxman DJ, Zhang L, Widman DG, Swanson KV, Wen KW, Damania B, Moore CB, Giguère PM, Siderovski DP, Hiscott J, Razani B, Semenkovich CF, Chen X, Ting JP.

Immunity. 2012 Jun 29;36(6):933-46. doi: 10.1016/j.immuni.2012.03.025.

34.

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Tseng A, Foisy M, Hughes CA, Kelly D, Chan S, Dayneka N, Giguère P, Higgins N, Hills-Nieminen C, Kapler J, la Porte CJ, Nickel P, Park-Wyllie L, Quaia C, Robinson L, Sheehan N, Stone S, Sulz L, Yoong D.

Can J Hosp Pharm. 2012 Mar;65(2):125-45. No abstract available.

35.

G-protein signaling modulator-3 regulates heterotrimeric G-protein dynamics through dual association with Gβ and Gαi protein subunits.

Giguère PM, Laroche G, Oestreich EA, Siderovski DP.

J Biol Chem. 2012 Feb 10;287(7):4863-74. doi: 10.1074/jbc.M111.311712. Epub 2011 Dec 13.

36.

Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets.

Kimple AJ, Bosch DE, Giguère PM, Siderovski DP.

Pharmacol Rev. 2011 Sep;63(3):728-49. doi: 10.1124/pr.110.003038. Epub 2011 Jul 7. Review.

37.

Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

Toy J, Giguère P, Kravcik S, la Porte CJ.

AIDS. 2011 Feb 20;25(4):541-2. doi: 10.1097/QAD.0b013e32834403cd. No abstract available.

PMID:
21293201
38.

RNA interference screen for RGS protein specificity at muscarinic and protease-activated receptors reveals bidirectional modulation of signaling.

Laroche G, Giguère PM, Roth BL, Trejo J, Siderovski DP.

Am J Physiol Cell Physiol. 2010 Sep;299(3):C654-64. doi: 10.1152/ajpcell.00441.2009. Epub 2010 Jun 23.

39.

Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.

Jacques AC, Giguère P, Zhang G, Touchie C, la Porte CJ.

Ann Pharmacother. 2010 Jan;44(1):202-6. doi: 10.1345/aph.1M489. Epub 2009 Dec 2.

PMID:
19955297
40.

HIV-HCV Co-infection therapeutic outcomes have not improved over time.

Cooper C, Costiniuk C, Giguère P.

HIV Clin Trials. 2009 May-Jun;10(3):203-6. doi: 10.1310/hct1003-203. No abstract available.

PMID:
19632960
41.

Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis.

Giguère P, la Porte C, Zhang G, Cameron B.

AIDS. 2009 Mar 27;23(6):740-2. doi: 10.1097/QAD.0b013e328328f79d. No abstract available.

PMID:
19279448
42.

Structure of the parathyroid hormone receptor C terminus bound to the G-protein dimer Gbeta1gamma2.

Johnston CA, Kimple AJ, Giguère PM, Siderovski DP.

Structure. 2008 Jul;16(7):1086-94. doi: 10.1016/j.str.2008.04.010. Retraction in: Structure. 2011 Aug 10;19(8):1200.

43.

The N-terminal coiled-coil domain of the cytohesin/ARNO family of guanine nucleotide exchange factors interacts with Galphaq.

Laroche G, Giguère PM, Dupré E, Dupuis G, Parent JL.

Mol Cell Biochem. 2007 Dec;306(1-2):141-52. Epub 2007 Sep 6.

PMID:
17846866
44.

Interactions between protease inhibitors and acid-reducing agents: a systematic review.

Béïque L, Giguère P, la Porte C, Angel J.

HIV Med. 2007 Sep;8(6):335-45. Review.

45.

The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face.

Kimple AJ, Willard FS, Giguère PM, Johnston CA, Mocanu V, Siderovski DP.

Biochim Biophys Acta. 2007 Sep;1774(9):1213-20. Epub 2007 Jun 29.

46.

Peroxiredoxin-4 interacts with and regulates the thromboxane A(2) receptor.

Giguère P, Turcotte ME, Hamelin E, Parent A, Brisson J, Laroche G, Labrecque P, Dupuis G, Parent JL.

FEBS Lett. 2007 Aug 7;581(20):3863-8. Epub 2007 Jul 17.

47.

ARF6 activation by Galpha q signaling: Galpha q forms molecular complexes with ARNO and ARF6.

Giguère P, Rochdi MD, Laroche G, Dupré E, Whorton MR, Sunahara RK, Claing A, Dupuis G, Parent JL.

Cell Signal. 2006 Nov;18(11):1988-94. Epub 2006 Mar 14.

PMID:
16650966
48.

Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.

Antoniou T, Tseng AL, van Heeswijk RP, Walker SE, Giguere P, Phillips EJ.

Ther Drug Monit. 2005 Dec;27(6):779-81.

PMID:
16306854
49.

Oligomerization of the alpha and beta isoforms of the thromboxane A2 receptor: relevance to receptor signaling and endocytosis.

Laroche G, Lépine MC, Thériault C, Giguère P, Giguère V, Gallant MA, de Brum-Fernandes A, Parent JL.

Cell Signal. 2005 Nov;17(11):1373-83.

PMID:
15893915
50.

Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW.

Br J Clin Pharmacol. 2005 Apr;59(4):398-404.

Supplemental Content

Loading ...
Support Center